Core Viewpoint - The announcement of a mid-term performance delay and trading suspension by Rier Group has revealed a long-standing "circular borrowing" transaction involving a $11 million loan to a company wholly owned by the founder, which raises concerns about potential financial misconduct [1][10]. Group 1: Loan and Financial Transactions - Rier Group provided a $11 million loan to Beier Holdings Limited, a company controlled by founder Zou Qifang, with the loan's repayment timeline and amounts closely matching several suspicious payments made by Rier Group [1][4]. - The loan was initially set for 9 months at a 4.5% interest rate, but it has been extended multiple times, with the latest extension pushing the maturity to 30 months and increasing the interest rate to 5.5% [4][6]. - As of June 27, 2025, Beier Holdings Limited had repaid a total of $3.5 million, with further repayments scheduled but not fulfilled, leading to additional extensions [3][6]. Group 2: Impact on Stock and Market Position - Rier Group's stock price has significantly declined from a peak of HKD 16.020 in March 2023 to HKD 1.830 before the trading suspension, reflecting a total market capitalization of HKD 1.029 billion [5][6]. - The collateral for the loan has also diminished in value due to the stock price drop, raising concerns about the adequacy of the guarantees provided by Zou Qifang [5][10]. Group 3: Audit and Investigation - The auditing firm PwC has raised questions about the timing and nature of certain payments made by Rier Group, suggesting the need for an independent investigation to clarify the situation [4][11]. - Rier Group has acknowledged the need for further investigation and has suspended trading until the mid-term performance report is published [3][11]. Group 4: Historical Context and Corporate Governance - The borrowing arrangement dates back to 2017 during a critical financing round, where Zou Qifang used funds from Rier Group to acquire shares, creating a cycle of borrowing and pledging shares [9][10]. - The company has faced significant operational challenges, with a net loss of CNY 1.52 billion from 2021 to 2023, and only recently achieved profitability in the 2024 fiscal year [12][11].

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued an administrative penalty notice to Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for suspected false financial reporting, indicating a significant regulatory crackdown on financial misconduct in the market [1][5]. Group 1: Regulatory Actions - The CSRC has initiated an administrative penalty against *ST Changyao for suspected false records in periodic reports and financial data [1]. - The Shenzhen Stock Exchange will commence delisting procedures due to *ST Changyao's involvement in major illegal activities that could lead to forced delisting [2]. - The CSRC plans to investigate the practices of intermediary institutions involved with *ST Changyao [1][16]. Group 2: Financial Misconduct - *ST Changyao has been found to have inflated revenue and profits for three consecutive years (2021-2023), violating securities laws [5]. - The company reported inflated revenues of 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan for the years 2021, 2022, and 2023, respectively, representing 9.12%, 17.57%, and 19.51% of the disclosed revenue [5]. - The inflated profit totals were 56.40 million yuan, 63.38 million yuan, and 43.71 million yuan for the same years, accounting for 35.62%, 88.23%, and 6.42% of the disclosed profit [5]. Group 3: Company Background - *ST Changyao, originally known as Kangyue Technology, was established in 2001 and listed on the Shenzhen Stock Exchange in August 2014 [6]. - The company entered the pharmaceutical industry in 2020 after acquiring a majority stake in Hubei Changjiang Star Pharmaceutical Co., Ltd. [6]. - The former actual controller, Luo Ming, continued to manage the company and was involved in the financial misconduct [6]. Group 4: Financial Health and Risks - As of the end of 2024, *ST Changyao reported a negative net asset of -432.84 million yuan and a significant decline in revenue from 1.615 billion yuan in 2022 to 112 million yuan in 2024 [10][12]. - The company faces multiple risks, including potential bankruptcy due to failure to meet restructuring conditions and significant overdue debts [12][14]. - The company has been under investigation since November 7, and the regulatory environment has tightened, leading to a record number of companies facing forced delisting this year [1][18].

来源：环球网 【环球网综合报道】12月26日，长江医药控股股份有限公司（*ST长药（维权），以下简称"长江医 药"）公告提示多个重要风险。 长江医药称，根据收到的《告知书》认定情况，公司股票可能被实施重大违法强制退市，公司股票于 2025年12月29日（星期一）起被叠加实施退市风险警示。此外，公司可能触及《深圳证券交易所创业板 股票上市规则》第10.5.2条第（六）项规定的"根据中国证监会行政处罚决定载明的事实，公司披露的年 度报告财务指标连续三年存在虚假记载，前述财务指标包括营业收入、利润总额、净利润、资产负债表 中的资产或者负债科目"的重大违法强制退市情形，公司股票可能被实施重大违法强制退市。 除触及重大违法强制退市情形外，*ST长药还面临财务类强制退市压力。2024年末公司归属于上市公司 股东的净资产为-4.33亿元，2025年三季度末该指标进一步恶化至-6.43亿元，若2025年年报审计后净资 产仍为负值，公司股票将被实施财务类强制退市。 经营层面，*ST长药早已隐患重重。截至2024年末，公司合并报表未分配利润为-15.90亿元，2024年净 利润亏损6.28亿元，经营净现金流量连续三年为负，累计亏 ...

根据《深圳证券交易所创业板股票上市规则》，如根据正式的处罚决定书结论，公司触及重大违法强制 退市情形，公司股票将被终止上市，公司股票于2025年12月29日（星期一）起被叠加实施退市风险警 示。 公告显示，公司2021年、2022年、2023年年度报告存在虚假记载，2021年至2023年年度报告分别虚增营 业收入21,532.38万元、28,373.66万元、23,363.46万元，占当期对外披露营业收入的9.12%、17.57%、 19.51%；虚增利润总额5,640.14万元、6,337.52万元、4,370.50万元，占当期对外披露利润总额绝对值的 35.62%、88.23%、6.42%。同时，由于2022年对长江伟创中药城交易中心工程项目未合理确认损失，导 致公司2022年年度报告虚增利润总额455.24万元，占当期对外披露利润总额的6.34%。 近日，长江医药发布公告称，公司及相关人员因涉嫌定期报告等财务数据虚假记载，被中国证监会立案 调查。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 目前，*ST长药正陷入多重危机：旗下光伏子公司河北羿珩科技因资金紧张已停产；公司涉及多起诉讼，涉案金额累计超1.5亿元。财务造假、经营困境与退 市风险相互交织，使其成为资本市场又一高风险案例。截至2025年三季度末，*ST长药股东户数超1.4万户，绝大多数为中小投资者。随着退市临近，投资者 面临本金归零风险，而现有处罚机制能否转化为有效赔偿，成为市场关注焦点。 系统虚增利润超1.6亿 证监会调查显示，*ST长药本次财务造假行为具有系统性、跨年度特征，主要源于其于2020年以现金方式收购的控股子公司湖北长江星医药股份有限公司。 公开资料显示，收购完成后，长江星原实际控制人罗明继续担任该公司董事长、总经理，全面负责经营管理，并对2020年至2022年的净利润等指标作出了业 绩承诺。此次造假正是发生在业绩承诺期及后续期间。 根据证监会《行政处罚事先告知书》及公司相关公告，造假的具体实施主体为长江星旗下两家子公司，湖北长江源制药有限公司和湖北新峰制药有限公司。 在2021年至2023年期间，这两家子公司通过制作虚假的原材料入库单、产成品出库单、销售发货单等全套单据，在 ...

Core Viewpoint - The former secretary of the board of directors of Ankao Zhidian, Huang Jiegen, was sentenced to 7 years in prison for attempted extortion and fined 100,000 yuan, which has raised concerns about the company's governance and financial practices [1][6][12]. Company Overview - Ankao Zhidian (300617.SZ) specializes in the innovative research and development of cable connection systems, GIL systems, and smart modular substations [3][14]. - The company’s stock price peaked at 91.38 yuan per share in 2021 but has remained below 50 yuan for most of this year, closing at 32.3 yuan on December 26, with a total market capitalization of approximately 5.4 billion yuan [6][12][17]. Financial Performance - For the first three quarters of this year, Ankao Zhidian reported revenue of approximately 457 million yuan, a year-on-year decrease of 31.66%, and a net profit attributable to shareholders of about 73.82 million yuan, down 45.72% year-on-year [6][12][17]. Legal Issues - Huang Jiegen was accused of extortion related to alleged financial fraud within the company, claiming he discovered discrepancies in financial reports but was reported for extortion when he refused to cooperate [7][18]. - The prosecution indicated that Huang attempted to leverage the company's financial issues to demand substantial financial compensation [7][18]. - Huang claimed that during his tenure, he received multiple versions of the 2022 semi-annual report with differing net profit figures, suggesting potential revenue inflation [21][22]. Regulatory Actions - Ankao Zhidian received a warning from the Jiangsu Securities Regulatory Bureau for three violations, including inaccurate revenue recognition policies and inadequate internal controls [22]. - The company announced corrections to prior accounting errors, adjusting its 2022 semi-annual report to reflect a revenue reduction of 4.5 million yuan and a net profit increase of 634,390 yuan, indicating prior misreporting [23].

Group 1 - ST Taiyuan Heavy Industry and several executives received disciplinary actions for information disclosure violations as announced by the Shanghai Stock Exchange on December 26, 2025 [1] - The responsible individuals include former General Manager Fan Weimin, former Chairman Wang Chuangmin, and others, who were involved in the misrepresentation of financial data [1][3] - The company overstated revenue and costs from 2012 to 2021, leading to false records in annual reports for multiple years, including a reported overstatement of operating income by 757 million yuan in 2014, which accounted for 8.39% of the disclosed operating income for that period [3] Group 2 - The China Securities Regulatory Commission (CSRC) imposed a total fine of 16.95 million yuan on ST Taiyuan Heavy Industry and its executives, with specific penalties for each individual based on the severity of their violations [4][6] - Fan Weimin received a lifetime ban from the securities market due to the severity of his violations, while Wang Chuangmin and others received bans ranging from 3 to 10 years [6] - The company was also ordered to correct its practices and received a warning along with a fine of 8 million yuan [4] Group 3 - For the first three quarters of 2025, ST Taiyuan Heavy Industry reported operating revenue of 7.028 billion yuan, a year-on-year increase of 10.0%, and a net profit attributable to shareholders of 85.06 million yuan, up 21.8% [7] - The company’s total assets reached 32.388 billion yuan by the end of the third quarter, reflecting a 3.6% increase from the previous year, while the net assets attributable to shareholders decreased by 3.1% to 5.094 billion yuan [8]

Core Viewpoint - Long Pharmaceutical Holdings (ST Changyao) is facing a severe crisis due to financial fraud, leading to a potential delisting from the stock market and significant losses for its investors [2][4]. Group 1: Financial Fraud Details - Long Pharmaceutical Holdings has been found to have inflated its revenue by over 700 million yuan from 2021 to 2023, with specific annual increases of 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan, representing 9.12%, 17.57%, and 19.51% of the reported revenue for those years respectively [4][5]. - The company also inflated its total profit by approximately 56.4 million yuan, 63.4 million yuan, and 43.7 million yuan during the same period, accounting for 35.62%, 88.23%, and 6.42% of the reported total profit [4][5]. - The fraud was facilitated by subsidiaries of Long Pharmaceutical Holdings, which created false inventory and sales documents without actual sales occurring [4][5]. Group 2: Regulatory Actions - The China Securities Regulatory Commission (CSRC) has issued a preliminary administrative penalty notice, proposing a total fine of 41 million yuan against Long Pharmaceutical Holdings and 14 responsible individuals, with the company itself facing a fine of 10 million yuan [5][6]. - The CSRC has classified the case as a serious financial fraud incident, indicating that it may trigger mandatory delisting procedures [5][6]. - The CSRC is also investigating the performance of the auditing firms involved, and any violations found will lead to further penalties [5][6]. Group 3: Investor Impact - Investors are facing dual risks of delisting due to financial indicators and serious violations, with the stock price having dropped over 70% in 2025, closing at 1.47 yuan per share [7][10]. - There are potential legal avenues for investors to seek compensation for losses incurred due to the financial fraud, particularly for those who held shares during specified periods [10][11]. - The company has acknowledged the situation and stated it will cooperate with the CSRC, but the final outcome will depend on the formal penalty decision [6][10].

Group 1 - The 14th National People's Congress (NPC) will convene on March 5, 2026, in Beijing as decided by the Standing Committee of the National People's Congress [4] - The 14th National Committee of the Chinese People's Political Consultative Conference (CPPCC) is suggested to hold its meeting on March 4, 2026, in Beijing [4]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has announced severe penalties against Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for serious financial fraud, which includes a proposed fine of 10 million yuan for the company and 31 million yuan for 14 responsible individuals, along with a lifetime ban for the former general manager, Luo Ming [4][6]. Financial Fraud Details - *ST Changyao has inflated its revenue and profits for three consecutive years, violating securities laws. The company is facing a potential forced delisting due to these serious violations [4][7]. - The company reported inflated revenues of 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan for the years 2021, 2022, and 2023, respectively, which accounted for 9.12%, 17.57%, and 19.51% of the disclosed revenue for those years [6]. - The inflated profit totals were 56.40 million yuan, 63.38 million yuan, and 43.71 million yuan for the same years, representing 35.62%, 88.23%, and 6.42% of the disclosed profit totals [6]. Regulatory Actions - The CSRC has initiated an investigation into the practices of intermediary institutions involved, with potential penalties for any violations found [4][6]. - The company is the 15th listed firm this year to face potential forced delisting due to financial fraud [4]. Company Performance - *ST Changyao has reported continuous losses, with a net profit of -210 million yuan for the first three quarters of 2025, a year-on-year decrease of 15.89% [8]. - The stock price has been declining since the investigation began, closing at 1.47 yuan per share on December 26, with a total market value of only 515 million yuan [10].